A novel oncogene AHI-1 interacts with BCR-ABL and JAK2 and mediates cellular resistance to tyrosine kinase inhibitors in CML
Chronic myeloid leukemia is a myeloproliferative disorder characterized by the presence of the Philadelphia chromosome, encoding a unique fusion gene BCR-ABL. The current first line treatment for patients diagnosed with CML involves administration of the ABL kinase inhibitor imatinib mesylate (IM)....
| Main Author: | |
|---|---|
| Language: | English |
| Published: |
University of British Columbia
2010
|
| Online Access: | http://hdl.handle.net/2429/24851 |